Women in clinical studies
General Accounting Office follow-up report on FDA practices for inclusion of women in clinical drug trials requested by Sens. Harkin (D-Iowa), Mikulski (D-Md.) and Snowe (R-Maine) and Rep. Waxman (D-Calif.) in a May 2 letter. The report will assess changes that have occurred since a 1992 GAO report found inadequate representation of women in clinical trials. FDA issued a proposed rule in 1997 that would require inclusion of women of child-bearing potential in trials
You may also be interested in...
Improving the monitoring of drug adverse events is one of FDA's main challenges, a General Accounting Office transition report on HHS indicates.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011